ArticleIBRO neuroscience reports2026

A feasibility open-label clinical trial utilizing second-generation artificial intelligence based on the constrained-disorder principle in patients with Parkinson's disease.

Hillel Lehmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.